SCINAI IMMUNOTHERAPEUTICS LTD. Research And Development Expense
SCINAI IMMUNOTHERAPEUTICS LTD. (SCNI) reported Research And Development Expense of ILS 6.50 million for the 3-month period ending 2022-06-30, per its 6-K/A filed 2022-08-29.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2022-08-29
- SCINAI IMMUNOTHERAPEUTICS LTD. research and development expense for the quarter ending 2022-06-30 was 6.50M ILS, a 241.84% increase year-over-year.
- SCINAI IMMUNOTHERAPEUTICS LTD. research and development expense for the quarter ending 2021-12-31 was 3.66M ILS, a 53.43% decline year-over-year.
- SCINAI IMMUNOTHERAPEUTICS LTD. research and development expense for the quarter ending 2021-09-30 was 2.02M ILS, a 83.91% decline year-over-year.
- SCINAI IMMUNOTHERAPEUTICS LTD. research and development expense for the quarter ending 2021-06-30 was 1.90M ILS, a 84.10% decline year-over-year.
ILS
| Period end | Research And Development Expense 3 month | Research And Development Expense 6 month | Research And Development Expense 9 month | Research And Development Expense 12 month |
|---|---|---|---|---|
| 2022-06-30 | 6.50M ILS 6-K/A · filed 2022-08-29 | 10.15M ILS 6-K/A · filed 2022-08-29 | ||
| 2021-12-31 | 3.66M ILS derived: 6-K/A 12 month − 6-K/A 9 month · filed 2022-08-29 | 5.69M ILS derived: sum of 2 quarters · filed 2022-08-29 | 7.59M ILS derived: sum of 3 quarters · filed 2022-08-29 | 10.34M ILS 6-K/A · filed 2022-08-29 |
| 2021-09-30 | 2.02M ILS 6-K/A · filed 2021-12-27 | 3.92M ILS derived: sum of 2 quarters · filed 2022-08-29 | 6.68M ILS 6-K/A · filed 2021-12-27 | |
| 2021-06-30 | 1.90M ILS 6-K/A · filed 2022-08-29 | 4.65M ILS 6-K/A · filed 2022-08-29 | ||
| 2020-12-31 | 7.87M ILS derived: 20-F 12 month − 6-K/A 9 month · filed 2022-03-28 | 20.45M ILS derived: sum of 2 quarters · filed 2022-03-28 | 32.40M ILS derived: sum of 3 quarters · filed 2022-03-28 | 51.46M ILS 20-F · filed 2022-03-28 |
| 2020-09-30 | 12.58M ILS 6-K/A · filed 2021-12-27 | 24.53M ILS derived: sum of 2 quarters · filed 2021-12-27 | 43.59M ILS 6-K/A · filed 2021-12-27 | |
| 2020-06-30 | 11.95M ILS 6-K · filed 2020-10-02 | 31.02M ILS 6-K · filed 2020-10-02 | ||
| 2019-12-31 | 31.61M ILS derived: 20-F 12 month − 6-K 9 month · filed 2022-03-28 | 47.74M ILS derived: sum of 2 quarters · filed 2022-03-28 | 62.91M ILS derived: sum of 3 quarters · filed 2022-03-28 | 68.64M ILS 20-F · filed 2022-03-28 |
| 2019-09-30 | 16.13M ILS 6-K · filed 2021-01-28 | 31.30M ILS derived: sum of 2 quarters · filed 2021-01-28 | 37.04M ILS 6-K · filed 2021-01-28 | |
| 2019-06-30 | 15.17M ILS 6-K · filed 2020-10-02 | 20.90M ILS 6-K · filed 2020-10-02 | ||
| 2018-12-31 | 71.91M ILS 20-F · filed 2021-05-13 | |||
| 2017-12-31 | 18.78M ILS 20-F · filed 2020-06-12 | |||
| 2016-12-31 | 7.79M ILS 20-F · filed 2019-04-30 | |||
| 2015-12-31 | 7.91M ILS 20-F · filed 2018-04-30 |
USD
| Period end | Research And Development Expense 3 month | Research And Development Expense 6 month | Research And Development Expense 9 month | Research And Development Expense 12 month |
|---|---|---|---|---|
| 2022-06-30 | $2.90M 6-K/A · filed 2022-08-29 | |||
| 2021-12-31 | $1.26M derived: 20-F 12 month − 6-K/A 9 month · filed 2022-03-28 | $3.33M 20-F · filed 2022-03-28 | ||
| 2021-09-30 | $2.07M 6-K/A · filed 2021-12-27 | |||
| 2020-12-31 | $16.01M 20-F · filed 2021-05-13 | |||
| 2017-12-31 | $5.42M 20-F · filed 2018-04-30 |